May 20, 2026 – The highly anticipated 2026 Pharmaceutical Investment & Financing Transaction Conference was held in Shanghai, bringing together industry leaders to explore innovation, partnerships and investment. Dr. H Fai Poon, Chief Executive Officer of Sirnaomics, was invited to deliver a keynote speech at the high-potential program showcase, where he presented pivotal updates on the company’s core pipeline and disclosed dual breakthroughs achieved through the proprietary PNP extrahepatic delivery platform and the GalAhead™ systemic delivery platform.

During his presentation, Dr. Poon elaborated on the broad business development opportunities emerging across the global oligonucleotide therapeutics landscape and highlighted Sirnaomics’ differentiated pipeline advantages in oncology, medical aesthetics (including localized fat reduction), and cardiovascular diseases. He emphasized that STP705, powered by the unique PNP delivery technology, has successfully demonstrated safety and efficacy in Phase II clinical trials for extrahepatic indications. Notably, with these results, the PNP platform is now among the very few nucleic acid delivery platforms globally to have generated Phase II clinical data for extrahepatic targets, strongly validating its ability to overcome long-standing extrahepatic delivery barriers.

Concurrently, Phase I clinical data for STP122G, an FXI-targeted siRNA, were disclosed. The candidate exhibited an excellent safety profile and clear dose-response relationships, together with preliminary signals of biological activity. As one of the most advanced FXI siRNA programs currently in clinical development in the United States, STP122G is accelerating toward potentially becoming the first independently developed FXI-targeted siRNA therapy to receive U.S. regulatory approval — offering a wholly new treatment option for patients.

Through the conference, Sirnaomics not only demonstrated its core competitiveness in delivery technology, clinical execution and global strategic deployment, but also clearly conveyed its firm commitment to advancing global business development collaborations with an open posture and to accelerating the delivery of innovative therapies to patients. The presentation attracted substantial attention from both industry peers and the investment community.

About Sirnaomics

Sirnaomics Ltd.(HK: 2257), known as Asia's "First RNAi Therapeutics Stock," is a clinical-stage global biopharmaceutical company specializing in RNA interference technology. Utilizing its dual core technology platforms and diverse pipeline, the company is at the forefront of developing RNAi therapies to drive industry growth.

Sirnaomics has two proprietary delivery platforms:

1. Polypeptide Nanoparticle (PNP) Platform: An extrahepatic delivery platform enabling precise targeting of tissues such as skin, adipose tissue, and muscle.
2. GalAhead™ Delivery Platform: A liver-targeted delivery system with clear IP and long-acting administration capabilities.

The company is also an industry leader with its innovative linker-free, dual-target RNAi technology. Sirnaomics' robust pipeline addresses oncology, local fat reduction, medical aesthetics, and cardiovascular diseases, with multiple products in clinical trials. Beyond its internal development, Sirnaomics embraces an open-collaboration strategy, integrating its technology platforms to support the broader industry and benefit patients worldwide.